Stability of lysozyme incorporated into electrospun fibrous mats for wound healing

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. / Liu, Xiaoli; Nielsen, Line Hagner; Qu, Haiyan; Christensen, Lars Porskjær; Rantanen, Jukka; Yang, Mingshi.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 136, 01.03.2019, p. 240-249.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Liu, X, Nielsen, LH, Qu, H, Christensen, LP, Rantanen, J & Yang, M 2019, 'Stability of lysozyme incorporated into electrospun fibrous mats for wound healing', European Journal of Pharmaceutics and Biopharmaceutics, vol. 136, pp. 240-249. https://doi.org/10.1016/j.ejpb.2019.01.003

APA

Liu, X., Nielsen, L. H., Qu, H., Christensen, L. P., Rantanen, J., & Yang, M. (2019). Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. European Journal of Pharmaceutics and Biopharmaceutics, 136, 240-249. https://doi.org/10.1016/j.ejpb.2019.01.003

Vancouver

Liu X, Nielsen LH, Qu H, Christensen LP, Rantanen J, Yang M. Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. European Journal of Pharmaceutics and Biopharmaceutics. 2019 Mar 1;136:240-249. https://doi.org/10.1016/j.ejpb.2019.01.003

Author

Liu, Xiaoli ; Nielsen, Line Hagner ; Qu, Haiyan ; Christensen, Lars Porskjær ; Rantanen, Jukka ; Yang, Mingshi. / Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. In: European Journal of Pharmaceutics and Biopharmaceutics. 2019 ; Vol. 136. pp. 240-249.

Bibtex

@article{ae9143dfaeac4a28bda8269ae86b9452,
title = "Stability of lysozyme incorporated into electrospun fibrous mats for wound healing",
abstract = "In this study, we investigated the feasibility of incorporating protein drugs into electrospun fibrous mats (EFMs) for wound healing using lysozyme as a model drug. Lysozyme nanoparticles (Lyso- NPs) were first obtained by electrospray. Lysozyme solutions were prepared with a binary solvent mixture of ethanol (EtOH)-water (H 2 O) at varied volume ratios. Subsequently, Lyso-NPs were suspended in poly(lactic-co-glycolic acid) (PLGA) solutions using trifluoroethanol (TFE) as a solvent. Lyso-NPs loaded EFMs were obtained by electrospinning of the aforementioned suspensions, and the bioactivity of lysozyme in the EFMs was investigated using fluorescence-based assay kit. The electrosprayed Lyso-NPs were spherical with barely altered bioactivity as compared to the untreated raw material when using EtOH- H 2 O (30:70, v/v) as the solvent. After the subsequent electrospinning process, more than 90{\%} of the bioactivity of lysozyme was retained compared to the raw material. The cytotoxicity of the produced EFMs was evaluated by thiazolyl blue tetrazolium bromide (MTT) study and the proliferation and distribution of mouse fibroblast cells (L929) growing on EFMs were investigated using 4,6-diamidino-2-phenylindol dihydrochloride (DAPI) for nucleic acid staining. Nearly negligible cytotoxicity of all the EFMs was observed according to the MTT study. Furthermore, it was observed that the L929 cells grew well on the Lyso-EFMs, especially those with the modification of polyethylene glycol (PEG) that was added to improve the hydrophilicity of EFMs. This study demonstrated that the electrospray/electrospinning processes are suitable for loading biomacromolecules to produce functionalized wound dressings to promote wound healing.",
keywords = "Bioactivity, Cell growth, Electrospinning, Electrospray, Protein, Wound healing",
author = "Xiaoli Liu and Nielsen, {Line Hagner} and Haiyan Qu and Christensen, {Lars Porskj{\ae}r} and Jukka Rantanen and Mingshi Yang",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ejpb.2019.01.003",
language = "English",
volume = "136",
pages = "240--249",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Stability of lysozyme incorporated into electrospun fibrous mats for wound healing

AU - Liu, Xiaoli

AU - Nielsen, Line Hagner

AU - Qu, Haiyan

AU - Christensen, Lars Porskjær

AU - Rantanen, Jukka

AU - Yang, Mingshi

PY - 2019/3/1

Y1 - 2019/3/1

N2 - In this study, we investigated the feasibility of incorporating protein drugs into electrospun fibrous mats (EFMs) for wound healing using lysozyme as a model drug. Lysozyme nanoparticles (Lyso- NPs) were first obtained by electrospray. Lysozyme solutions were prepared with a binary solvent mixture of ethanol (EtOH)-water (H 2 O) at varied volume ratios. Subsequently, Lyso-NPs were suspended in poly(lactic-co-glycolic acid) (PLGA) solutions using trifluoroethanol (TFE) as a solvent. Lyso-NPs loaded EFMs were obtained by electrospinning of the aforementioned suspensions, and the bioactivity of lysozyme in the EFMs was investigated using fluorescence-based assay kit. The electrosprayed Lyso-NPs were spherical with barely altered bioactivity as compared to the untreated raw material when using EtOH- H 2 O (30:70, v/v) as the solvent. After the subsequent electrospinning process, more than 90% of the bioactivity of lysozyme was retained compared to the raw material. The cytotoxicity of the produced EFMs was evaluated by thiazolyl blue tetrazolium bromide (MTT) study and the proliferation and distribution of mouse fibroblast cells (L929) growing on EFMs were investigated using 4,6-diamidino-2-phenylindol dihydrochloride (DAPI) for nucleic acid staining. Nearly negligible cytotoxicity of all the EFMs was observed according to the MTT study. Furthermore, it was observed that the L929 cells grew well on the Lyso-EFMs, especially those with the modification of polyethylene glycol (PEG) that was added to improve the hydrophilicity of EFMs. This study demonstrated that the electrospray/electrospinning processes are suitable for loading biomacromolecules to produce functionalized wound dressings to promote wound healing.

AB - In this study, we investigated the feasibility of incorporating protein drugs into electrospun fibrous mats (EFMs) for wound healing using lysozyme as a model drug. Lysozyme nanoparticles (Lyso- NPs) were first obtained by electrospray. Lysozyme solutions were prepared with a binary solvent mixture of ethanol (EtOH)-water (H 2 O) at varied volume ratios. Subsequently, Lyso-NPs were suspended in poly(lactic-co-glycolic acid) (PLGA) solutions using trifluoroethanol (TFE) as a solvent. Lyso-NPs loaded EFMs were obtained by electrospinning of the aforementioned suspensions, and the bioactivity of lysozyme in the EFMs was investigated using fluorescence-based assay kit. The electrosprayed Lyso-NPs were spherical with barely altered bioactivity as compared to the untreated raw material when using EtOH- H 2 O (30:70, v/v) as the solvent. After the subsequent electrospinning process, more than 90% of the bioactivity of lysozyme was retained compared to the raw material. The cytotoxicity of the produced EFMs was evaluated by thiazolyl blue tetrazolium bromide (MTT) study and the proliferation and distribution of mouse fibroblast cells (L929) growing on EFMs were investigated using 4,6-diamidino-2-phenylindol dihydrochloride (DAPI) for nucleic acid staining. Nearly negligible cytotoxicity of all the EFMs was observed according to the MTT study. Furthermore, it was observed that the L929 cells grew well on the Lyso-EFMs, especially those with the modification of polyethylene glycol (PEG) that was added to improve the hydrophilicity of EFMs. This study demonstrated that the electrospray/electrospinning processes are suitable for loading biomacromolecules to produce functionalized wound dressings to promote wound healing.

KW - Bioactivity

KW - Cell growth

KW - Electrospinning

KW - Electrospray

KW - Protein

KW - Wound healing

U2 - 10.1016/j.ejpb.2019.01.003

DO - 10.1016/j.ejpb.2019.01.003

M3 - Journal article

C2 - 30630062

AN - SCOPUS:85060980670

VL - 136

SP - 240

EP - 249

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -

ID: 221825477